Patent classifications
A61K2035/128
ELUTING MATRIX AND USES THEREOF
CXCL12 polypeptide eluting matrices encapsulating at least one cell are described for use in the treatment of autoimmune disorders.
MATERIALS WITH IMPROVED PROPERTIES
Products, such as devices, prostheses, and materials, whose surfaces have been modified in order to impart beneficial properties to these products are disclosed. The surface-modified products have improved biocompatibility compared to a corresponding product that lacks the modification. Following implantation in a subject, the surface-modified products induce a lower foreign-body response, compared to a corresponding unmodified product.
Synergistic curcuminoids and probiotic compositions
The current invention relates to the field of a novel probiotic-curcuminoids formulation, which exhibits increased curcuminoids bioavailability, and viable probiotic microbial population in the presence of curcuminoids. The probiotic-curcuminoids formulation is made by encapsulation in ragi and galactomannan-rich fenugreek dietary fiber matrix. Compositions and methods for making this formulation are also disclosed herein.
IMPLANTABLE THERAPEUTIC DELIVERY SYSTEM AND METHODS THEREOF
The present invention relates to an implantable therapeutic delivery system, methods of treatment utilizing the implantable therapeutic delivery system, and methods of fabricating the implantable delivery system. A first aspect of the present invention is directed to an implantable therapeutic delivery system. This therapeutic delivery system comprises a substrate, an inner polymeric coating that surrounds the substrate, and an outer hydrogel coating that surrounds said inner polymeric coating. One or more therapeutic agents are positioned in the outer hydrogel coating.
TREATMENT OF A DISEASE OF THE GASTROINTESTINAL TRACT WITH LIVE BIOTHERAPEUTICS
This disclosure features methods and compositions for treating diseases of the gastrointestinal tract with a live biothcrapeutic.
Methods for treating autism spectrum disorder and associated symptoms
The present disclosure relates to compositions and methods for treating autism spectrum disorder (ASD) by restoring an ASD patient's gut microbiota. These methods can be used with ASD patient with or without ongoing gastrointestinal symptoms. Provided here is a method for ASD treatment in a subject in need thereof comprising or consisting essentially of administering a therapeutic composition comprising a fecal microbe or a fecal microbiota preparation to the subject. Also provided here is a method comprises administering an antibiotic to a human subject; subjecting the human subject to a bowel cleanse; and administering purified fecal microbiota to the human subject. Further provided are evaluation and quantitative characterization of patient symptom improvements upon treatment described here.
METHOD FOR PRODUCING HYDROGEL MICROCAPSULES, KIT FOR PRODUCING CAPSULES, AND USE THEREFOR
A method for producing a capsule, including cooling a suspension so as to gel a thermoresponsive polymer including a core 8 formed from a gel of an ionically-bonded polymer and form a shell (17) of a hydrogel, the suspension being obtained by suspending, in oil (10), a sol (9) of the thermoresponsive polymer, and then using a chelating agent to solate the core so as to hollow out the inside.
Cell associated scaffolds for delivery of agents
The present invention relates to the use of scaffolds to enhance the viability of cells implanted in the integumentary system such that the cell may release an agent. The scaffold is capable of protecting the cell, as well as allowing for adequate nutrient delivery at the implant site through vascularisation in and around the scaffold.
Microcapsule and production method thereof
Disclosed is a microcapsule which is used in tissue regeneration, which may be specifically directed to the damaged tissues, and which forms an extracellular matrix-like structure at a certain point and thus allows cell proliferation, and to the production method of such microcapsule.
TRANSGENIC PIG ISLETS AND USES THEREOF FOR TREATING DIABETES
The present invention relates to an isolated transgenic pig beta cell wherein the PKC and the PKA pathway are constitutively activated; to a transgenic pig islet comprising said transgenic pig beta cell; and to a transgenic pig comprising said transgenic pig beta cell or said transgenic pig islet. Another object of the invention is a device comprising a transgenic pig beta cell or a transgenic pig islet of the invention. The present invention also relates to the use of said transgenic pig beta cell, said transgenic pig islet, or said device for treating a disease, disorder or condition related to the impaired function of endocrine pancreas or of beta cell.